Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.53 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5986952 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13089193 | 0.87 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL22698935 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL5987689 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL17787727 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HPGDCYP2C19FKBP1APDK1 | |
| SCHEMBL21543901 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HPGDCYP2C19FKBP1APDK1 | |
| SCHEMBL1150560 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HPGDCYP2C19FKBP1APDK1 | |
| SCHEMBL21561680 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HPGDCYP2C19FKBP1APDK1 | |
| SCHEMBL12862060 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HPGDCYP2C19FKBP1APDK1 | |
| SCHEMBL7495998 | 0.81 | FKBP1A (0.53) | ALDH1A1HPGDCYP2C19FKBP1APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313397-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10266525-B2 | Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| WO-2019016385-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2019-01-24 | — | — | WO | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150299178-A1 | Thiazole Derivatives as Alpha 7 NACHR Modulators | LUPIN LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| EP-2262808-B1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20110256128-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256128-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP17A1, CYP51A1, KLKB1 | CHRNB2 4062/4885CHRNA3 3684/4885CHRNA4 4219/4885 |
| US-20150299178-A1 | Thiazole Derivatives as Alpha 7 NACHR Modulators | CHRNA7, CHRM1, CHRM2 | CHRNB2 19/4885CHRNA3 15/4885CHRNA4 12/4885 |
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | CHRNB2 3365/4885CHRNA3 2562/4885CHRNA4 3153/4885 |
| US-10266525-B2 | Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole | IPO4, CYP3A4, CYP4B1 | CHRNB2 2472/4885CHRNA3 1569/4885CHRNA4 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.